Please find attached press release on financial results of the Company for Q1FY27

July 30, 2026 BSE Limited National Stock Exchange of India Limited P J Towers, Exchange Plaza, C-1, Block G, Dalal Street, Bandra Kurla Complex, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Scrip Code: 543904 Symbol: MANKIND Dear Sir/ Madam, Subject: Press Release – Q1 FY27 Ref: Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 Please find enclosed herewith the Press Release on Financial Results of the Company for the quarter ended on June 30, 2026. The above-mentioned Press Release is also being uploaded on the website of the company i.e. www.mankindpharma.com. You are requested to kindly take the above information on your records. Thanking You, Yours Faithfully, For Mankind Pharma Limited Hitesh Kumar Jain Company Secretary & Compliance Officer Encl.: A/a Press Release Strong Q1FY27 - Revenue growth of 13%; EBITDA growth of 25%; PAT growth of 29% New Delhi, India, 30th July, 2026: Mankind Pharma (BSE: 543904 | NSE: MANKIND) India’s fourth largest pharmaceutical Company today announced its financial results for the first quarter ended 30th June 2026. The information mentioned in this release is based on consolidated financial statements. Revenues Dom. Revenue* EBITDA INR 4,031 Crore INR 3,180 Crore INR 1,060 Crore Q1 FY27 12.9% YoY 11.0% YoY 24.7% YoY Note* - Domestic business excluding Consumer Healthcare Mr. Rajeev Juneja – Vice Chairman & Managing Director  Revenue grew ~13% YoY with EBITDA margins improving by 250bps to 26.3%  Overall domestic business (ex CH) grew by 11.0% led by:  Double digit growth in Mankind domestic business with 15.8% growth in Chronic - 19.4% in cardiac and 12.7% in anti-diabetes  Outperformance in Gastro, VMN, Gynaec led to growth recovery in acute  Strong double digit growth in BSV domestic specialty business  OTC segment grew by ~4%; while International business grew 29%  Our disciplined execution and strengthening business fundamentals, resulted in improvements across key operating and financial metrics in Q1FY27, laying the foundation to deliver long-term sustainable growth Q1 FY27 Performance Summary  Revenue from Operations at INR 4,031 Cr, up by 12.9% YoY o Domestic revenue at INR 3,426 Cr, up 10.5%, Exports at INR 605 Cr, up 29.0% YoY  EBITDA margin of 26.3%, up by 250 bps YoY and PAT margin of 14.2%, up 170 bps YoY  Diluted EPS1 of INR 13.7, up 29.6% YoY (FV Re.1) 1. Diluted EPS not annualised Press Release Domestic Business1  Domestic revenue (ex-Consumer Health)2 increased 11.0% YoY driven by double digit growth in Mankind business, supported by strong growth in BSV specialty business  Secondary sales growth of 12.7% vs 13.0% IPM3 in Q1FY27 – primarily due to: o strong performance in chronic growth supported by 19.4% in Cardiac and 12.7% in Anti- Diabetes3 o outperformance in Gastro (1.2x), VMN (1.2x), Gynaec (1.05x) led to growth recovery in acute, also recovery seen in anti-invectives (3.6% in Q1FY27 vs -1.1% in Q4FY26)  Strong growth in key focused brands: o outperformance in key acute brands like Cefakind-CV (1.2x), Nurokind-LC (1.1x), Pantakind (1.8x), Dydroboon (1.5x) etc. in Q1FY27 o 21% growth in Telmikind family; 30%/31% in Lipirose / Statpure in cardiac during Q1FY27 o Glizid brand family grew 29% YoY in Q1FY27  Healthy growth in BSVs key brands - Foligraf (39%), Humog (39%) and Anti-D (23%)  Consistently maintained #1 rank over last 9 years with prescription share of 15.2%1 1.As per IQVIA Jun-2026 // 2.Denotes reported number// 3. Ex-Trizepatide Consumer Healthcare Business1  Revenue growth2 of 4% YoY in Q1FY27 partly impacted by base effect of discontinued cash and carry business  Despite softer growth, we gained market share1 in key Brands – Manforce, Preganews and Gas-o-fast  MT & E-Com share increased to 15% in Q1FY27 as compared to 11% in Q1FY26 supported by 38% growth  Healthy growth in secondary sales for Gas-o-fast and Ova news of 10% and 36% YoY respectively in Q1FY27 1. As per IQVIA / IQVIA Retail, Jun-2026 // 2. Denotes reported number Exports  Revenue from International business1 registered healthy growth of 29% YoY in Q1FY27  Mankind (excluding BSV) has launched 1 new products in Q1FY27 taking the total launched products to 49 in US 1. Denotes reported number Press Release Consolidated Profit & Loss Account In INR Crore Q1 FY27 Q1 FY26 YoY% Q4 FY26 QoQ% Revenue from Operations 4,031 3,570 12.9% 3,443 17.1% Gross Margins % 72.8% 70.5% 230 bps 72.2% 60 bps EBITDA 1,060 850 24.7% 910 16.5% EBITDA Margin % 26.3% 23.8% 250 bps 26.4% -10 bps Adj. EBITDA 1,060 850 24.7% 9331 13.6% Adj. EBITDA Margin % 26.3% 23.8% 250 bps 27.1%1 -80 bps PAT 574 445 29.1% 559 2.6% PAT Margin % 14.2% 12.5% 170 bps 16.2% -200 bps 1. Adjusted with one time impact of labour code regulations Segmental Revenue Break Up In INR Crore Q1 FY27 Q1 FY26 YoY% Q4 FY26 QoQ% Domestic 3,426 3,101 10.5% 2,886 18.7%  Domestic (Ex-CH) 3,180 2,864 11.0% 2,673 19.0%  Consumer Healthcare 246 237 3.9% 213 15.5% Exports 605 469 29.0% 557 8.5% Total 4,031 3,570 12.9% 3,443 17.1% Earning concall Details Date 30th July, 2026 Time 06:30 pm – 07:30 pm IST Zoom Link Click here About Mankind Pharma Mankind Pharma (BSE: 543904 | NSE: MANKIND) is one of the largest pharmaceutical company in India, which focuses on the domestic market with its Pan India presence. Mankind operates at the intersection of the Indian pharmaceutical formulations and consumer healthcare sectors with the aim of providing quality products at affordable prices. The company is a leading player in the domestic pharmaceuticals business present across acute and chronic therapeutic areas including anti-infectives, cardiovascular, gastrointestinal, antidiabetic, neuro/CNS, gynaecology, VMN and respiratory, among others with a strategy to increase chronic presence going ahead. In the consumer healthcare business, the company operates in the condoms, pregnancy detection, emergency contraceptives, antacid powders, vitamin and mineral supplements and anti-acne preparations categories, among others, with several category-leading brands. Following the acquisition of BSV, Mankind Pharma has further strengthened its leadership in the domestic women’s health segment. Mankind's distribution network includes a robust field force of 18,500+ professionals, and a reach extending to over five lakh doctors across urban and rural markets. The company has 32 manufacturing facilities in India manufacturing a Press Release wide range of dosage forms, including tablets, capsules, syrups, vials, ampoules, blow fill seal, soft and hard gels, eye drops, creams, contraceptives and other over-the-counter products. Mankind has a consistent track record of product innovation through 7 dedicated R&D facilities backed by more than 740 scientists. For more information, visit www.mankindpharma.com Safe Harbour Statement The statements, are as on date and may contain forward-looking statements like the words “believe”, “expects”, “anticipate”, “aim”, “will likely result”, “Would”, “will continue”, “contemplate” “intends”, “plans”, “estimates”, “seek to”, “future”, “objective”, “projects”, “goal”, “likely”, “Project”, “should”, “potential” “will”, “may”, “targeting” or other words of similar expressions/ meaning regarding the financial position, business strategy, plans, targets and objectives of the Company. Such forward‐ looking statements involve known and unknown risks which may cause actual results, performance or achievements to be materially different from the results or achievements expressed or implied. The risks and uncertainties inter-alia, relating to these statements include (i) cash flow projections, (ii) industry and market conditions; (iii) ability to manage growth; (iv) competition; (v) government policies and regulations; (vi) obtaining regulatory approvals; (vii) domestic & international economic conditions such as interest rate & currency exchange fluctuations; (viii) political, econo [Showing first 8,000 characters — download PDF for full document]